STTK
Shattuck Labs Inc
$
1.860
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.860
Open
1.770
VWAP
1.77
Vol
34.71K
Mkt Cap
116.43M
Low
1.760
Amount
61.54K
EV/EBITDA(TTM)
--
Total Shares
47.55M
EV
30.30M
EV/OCF(TTM)
--
P/S(TTM)
103.50
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
--
--
-0.170
-29.17%
--
--
-0.170
-37.04%
--
--
-0.127
-65.57%
Estimates Revision
The market is revising No Change the revenue expectations for Shattuck Labs, Inc. (STTK) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 116.18%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-12.69%
In Past 3 Month
Stock Price
Go Up
+116.18%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast STTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STTK is 2.67 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 1.860
Low
2.00
Averages
2.67
High
4.00
Current: 1.860
Low
2.00
Averages
2.67
High
4.00
Wedbush
NULL
to
Outperform
initiated
$4
2025-09-08
Reason
Wedbush
Price Target
$4
2025-09-08
initiated
NULL
to
Outperform
Reason
Wedbush initiated coverage of Shattuck Labs with an Outperform rating and $4 price target.
Leerink
Faisal Khurshid
Outperform
to
Outperform
downgrade
$4 -> $2
2025-08-14
Reason
Leerink
Faisal Khurshid
Price Target
$4 -> $2
2025-08-14
downgrade
Outperform
to
Outperform
Reason
Leerink analyst Faisal Khurshid lowered the firm's price target on Shattuck Labs to $2 from $4 and keeps an Outperform rating on the shares after the company reported Q2 earnings and provided a pipeline update including expected Phase 1 trial initiation for SL-325 this quarter. The firm expects this to be a pivotal moment for Shattuck's turnaround story as the company transitions to a clinical-stage company, and thinks this should support new interest in its first-in-class DR3 approach in inflammatory bowel disease. Leerink notes that its change in price target is driven by additional shares outstanding, with minimal change in its other key modeling assumptions.
HC Wainwright & Co.
Joseph Pantginis
Hold
Reiterates
n/a
2025-03-27
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
n/a
2025-03-27
Reiterates
Hold
Reason
Needham
Gil Blum
Hold
Reiterates
n/a
2025-03-27
Reason
Needham
Gil Blum
Price Target
n/a
2025-03-27
Reiterates
Hold
Reason
Leerink Partners
Faisal Khurshid
Buy
Initiates
$4
2025-03-17
Reason
Leerink Partners
Faisal Khurshid
Price Target
$4
2025-03-17
Initiates
Buy
Reason
Leerink analyst Faisal A. Khurshid initiated coverage of Shattuck Labs with an Outperform rating and $4 price target. The firm views Shattuck Labs' pivot into inflammatory bowel disease as an underappreciated opportunity, with lead program SL-325 representing a first-in-class approach with potential to improve upon related, clinically validated, TL1A targeting programs. The company expects key Phase 1 milestones for SL-325 over the next 1 year, and Leerink is optimistic that these can spur investor interest in the turnaround story.
HC Wainwright & Co.
Joseph Pantginis
Hold
Reiterates
n/a
2024-11-15
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
n/a
2024-11-15
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Shattuck Labs Inc (STTK.O) is -3.53, compared to its 5-year average forward P/E of -5.40. For a more detailed relative valuation and DCF analysis to assess Shattuck Labs Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.40
Current PE
-3.53
Overvalued PE
1.70
Undervalued PE
-12.50
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.77
Current EV/EBITDA
-0.89
Overvalued EV/EBITDA
3.58
Undervalued EV/EBITDA
-9.12
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
433.04
Current PS
1.92
Overvalued PS
1473.23
Undervalued PS
-607.15
Financials
Annual
Quarterly
FY2025Q3
YoY :
-66.63%
1,000K
Total Revenue
FY2025Q3
YoY :
-40.20%
-10.72M
Operating Profit
FY2025Q3
YoY :
-39.69%
-10.06M
Net Income after Tax
FY2025Q3
YoY :
-57.58%
-0.14
EPS - Diluted
FY2025Q3
YoY :
-44.13%
-9.00M
Free Cash Flow
FY2025Q3
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q3
YoY :
+401.66%
-4.88K
FCF Margin - %
FY2025Q3
YoY :
+80.74%
-1.01K
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 6464.33% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
166.7K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
2
10.9M
USD
Months
6-9
0
0.0
USD
Months
0-12
1
166.7K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
75.8K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 6464.33% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
166.7K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
2
10.9M
USD
Months
6-9
0
0.0
USD
Months
0-12
1
166.7K
USD
Months
STTK News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
17:34:16
Shattuck Labs announces Q3 EPS of 14 cents, falling short of consensus estimate of 15 cents.
2025-08-21 (ET)
2025-08-21
10:18:55
Shattuck Labs announces IND approval for SL-325 to treat IBD.
2025-08-14 (ET)
2025-08-14
06:39:46
Shattuck Labs reports Q2 EPS (24c), consensus (25c)
Sign Up For More Events
Sign Up For More Events
News
1.0
10-02NewsfilterShattuck Labs to Take Part in Upcoming Wedbush Securities Key Opinion Leader and Company Panel
4.0
09-08NASDAQ.COMShattuck Labs (STTK) Receives Upgrade to Buy: Implications for the Stock
9.0
08-21NewsfilterShattuck Labs Confirms IND Approval for SL-325 to Treat Inflammatory Bowel Disease
Sign Up For More News
People Also Watch
AP
Ampco-Pittsburgh Corp
2.140
USD
-1.38%
RPID
Rapid Micro Biosystems Inc
4.045
USD
-9.30%
MAIA
Maia Biotechnology Inc
1.010
USD
0.00%
XPL
Solitario Resources Corp
0.580
USD
-2.69%
OTLK
Outlook Therapeutics Inc
1.590
USD
+8.16%
GROV
Grove Collaborative Holdings Inc
1.420
USD
-1.39%
SPRU
Spruce Power Holding Corp
5.150
USD
0.00%
OVID
Ovid Therapeutics Inc
1.260
USD
+5.00%
FTCI
FTC Solar Inc
10.520
USD
-4.62%
FAQ
What is Shattuck Labs Inc (STTK) stock price today?
The current price of STTK is 1.86 USD — it has increased 1.09 % in the last trading day.
What is Shattuck Labs Inc (STTK)'s business?
What is the price predicton of STTK Stock?
What is Shattuck Labs Inc (STTK)'s revenue for the last quarter?
What is Shattuck Labs Inc (STTK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Shattuck Labs Inc (STTK)'s fundamentals?
How many employees does Shattuck Labs Inc (STTK). have?